HomeLoginSite MapContact Us
Click to submit search
  Donate Now!

SMA ResearchFSMA CommunitySMA Fundraising
Newcompbanner
Donate Now
Registry

Connect with Families of SMA:

FacebookBanner

TwitterBanner

YouTubeBanner

 


Stem Cells

FSMA-Funded Stem Cell Research

The filing of an IND application is just the first step in a long and complicated process aimed ultimately at approval of a new therapy.  A likely outcome from this application was that the trial would be placed on clinical hold by the FDA.  A clinical hold is an order that the FDA issues to a sponsor to delay a proposed trial.   Each of the previous applications that have been submitted in this very new field of investigational stem cell treatments has been placed on clinical hold for approximately a year after the IND was filed.  FDA caution is not unusual for new therapeutic approaches.  Please click here for more on the clinical trial process. 

In January, the FDA placed the MotorGraft Program on clinical hold, in order to obtain additional data.  Please click here for that announcement.  

Program Milestones Over the Past Five Years, Enabled with FSMA Funding (please see funding tab above for specific details):

1. Proof-of-concept experiments showing motor neurons from mouse embryonic stem cells provided therapeutic benefit in a rodent model of motor neuron disease from the Kerr lab (Annals of Neurology, July 2006, 60: 32-44).

2. The successful production of motor neurons made from human embryonic stem for therapeutic use in humans from the Keirstead lab (See Figure 1, PLoS One, August 2010).


Figure 1. Human motor neurons produced at greater than 95% purity.
 

3. CSC develops methods for the manufacture of clinical grade human motor neurons from human embryonic stem cells.  This product is called MotorGraft.

4. In 2009, FSMA and SMA Europe co-funded a project reviewed by both our respective scientific advisory boards to the Comi Lab at the University of Milan called "Development of Therapeutic Strategies Based on Stem Cell Transplantation for SMA". Using two different sources of neural cell stem cells, this group has published two studies in peer-reviewed journals showing that a nursing effect of these cells when transplanted into the spinal cord of severe SMA mice (Delta7) prolongs survival and motor function. Please click here to see their papers in Brain and the Journal of Clinical Investigation. 

5. In a collaboration between Families of SMA, Hans Keirstead, and California Stem Cell, Inc. (CSC), the pivotal animal safety study, required to support an IND application to the FDA to begin clinical trials, was completed in October 2009.

6. In October 2009, CSC holds a pre-IND meeting with the FDA to discuss formal Investigational New Drug (IND) application to begin a Phase I/IIA clinical trial in SMA Type I. Please click here to see a recent press release by FSMA and CSC discussing the FDA pre-IND meeting.

7. In December, 2009 California Stem Cell, Inc. receives Orphan Designation for the MotorGraft Product from the FDA.  Please click here to read the press release. 

8. In December 2010, California Stem Cell Inc. Files IND to Commence Phase I Clinical Trial in Spinal Muscular, which was subsequently placed on clinical hold.  Please click here to read the press release. 

More detailed Information can be found in the history of program tab above.


 

Site Map Contact Us Privacy Policy Legal Terms & Conditions